Dr. Mayank Goyal Joins the Advisory Board of QuikFlo Health Inc.

CALGARY, ALBERTA--(Marketwired - Jan. 28, 2016) - QuikFlo Health Inc. ("QuikFlo" or the "Company") (TSX VENTURE:QF)(FRANKFURT:1QF) is pleased to announce that Dr. Mayank Goyal of Calgary, Alberta has joined its Advisory Board. Dr. Goyal is one of the founders of QuikFlo and the Director of Imaging and Intervention, Calgary Stroke Program at the University of Calgary. His main research interests are: Imaging in hyperacute stroke, treatment strategies for hyperacute stroke, and image post-processing. His recent works include increasing efficiency in treatment of hyperacute stroke and showing the benefit of endovascular treatment of acute ischemic stroke. He was one of the principal investigators for the ESCAPE trial and the SWIFT PRIME trial. Both these trials were recently published in the New England Journal of Medicine.

Vinny Jindal, the Company's President and CEO stated: "Dr. Goyal is world renown for his ground-breaking work in efficiency and workflow in acute stroke intervention. Dr. Goyal will bring this expertise to our company and enable us to further improve patient outcomes."

Dr. Goyal was granted 300,000 incentive stock options exercisable at $.25 for a period of 5 years pursuant to the Company's incentive stock option plan.

About QuikFlo

QuikFlo Health is a medical software company developing innovative solutions for the analysis of medical images. Our primary focus is on improving outcomes for stroke patients, where existing time delays are solvable through more efficient triage based on rapid, accurate analysis of medical images.

Further Information

For further information relating to the Company or this release please visit www.sedar.com or www.quikflohealth.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary and Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are currently reasonable, actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company's ability to identify and complete suitable acquisitions to further the Company's growth, the suitability of the key members of ongoing management and the board of directors, the biomedical and technology sectors in general such as operational risks in development, research and regulatory delays or changes in plans with respect to research projects or capital expenditures; the uncertainty of the market; the uncertainty of estimates and projections relating to costs and expenses; health, safety and environmental risks; marketing and commercialization; loss of markets; competition; ability to access sufficient capital; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws, and government regulations, and other risks identified in the recent information circular available on www.sedar.com. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive and additional risks and uncertainties are set forth in the circular.

No undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.